Vendor Intelligence Report: Inno Peptides

Executive summary

Across 17 Finnrick lab tests, Inno Peptides records 17 passes and 0 failures, for a 100% overall pass rate. The clean result is real but narrow: Finnrick’s sampled set covers Retatrutide, Tirzepatide, and GHK-Cu, not the vendor’s larger chemical catalog. GHK-Cu is the strongest-rated sampled product; Retatrutide and Tirzepatide provide the clearest GLP-1 signal, with ratings tightening under stricter grading.

The operating record is much rougher. Archived pages and LinkedIn materials attribute the brand to Wuhan INNO Technology Co., Ltd.; WHOIS and infrastructure checks show the main domain renewed after a retail outage but still parked on Alibaba expired-domain infrastructure during investigation. Community buyers reported continued fulfillment through direct-message channels, rotating aliases, crypto or wire-style payments, and no captured official channel-verification system.

The report’s most buyer-relevant work is disambiguation and product separation. Janoshik results circulating for the similarly named InnoPeptide trace to a different domain, while this vendor’s public record includes a “high copy” branded-HGH dispute, a LinkedIn blocking/payment complaint involving a named representative, an Instagram impersonation scam using the Inno name, and a Wuhan INNO/Innotech footprint extending into steroids, SARMs, intermediates, and NPS-type listings. The directional read: comparatively defensible only for Finnrick-sampled Retatrutide, Tirzepatide, and GHK-Cu; materially weaker for HGH, DSIP, steroid powders, raw materials, or unauthenticated DM orders.

Inside the full report:

• Appendix A laboratory table, pass/fail rates, methodology-divergence charts, and trajectories for all 3 sampled products
• Corporate attribution records linking innopeptides.com, Wuhan INNO Technology, the Wuhan address, and LinkedIn profile
• WHOIS, DNS, Wayback, and Spanish-subdomain analysis of the outage, renewal, and Alibaba parking state
• Channel and alias map covering Shin, Rosemary, Suri, Leslie, Belle, Sienna, Phoebe, Audrey, Loreler, and Lili Cheng
• Reputation and recourse review covering high-copy Jintropin, DSIP/underdosing allegations, impersonation, shipping, and payment rails

Risk assessment

• Counterfeit-product concern — high: 2024 records show Jintropin HGH sold as branded product failed verification and was acknowledged as a “high copy”; not tied to Finnrick-tested Retatrutide, Tirzepatide, or GHK-Cu.
• Brand-impersonation and channel-verification concern — high: Lili Cheng scam, similar InnoPeptide domain, rotating DM aliases, reported hacked Audrey account, and no captured official-channel/COA verification system make authentication difficult.
• High-risk chemical governance concern — high: Wuhan INNO/Innotech records market peptides beside steroids, SARMs, pharmaceutical intermediates, and NPS-type products without documented segregation or chain-of-custody controls.
• Dispute-handling and payment-recourse concern — high: Crypto/wire-style payments, no documented card chargeback path, and public blocking/payment complaints materially reduce buyer leverage when orders or tests go wrong.
• Non-Finnrick product quality-control concern — medium: Community allegations cite underdosing and an 88% DSIP purity result; Finnrick’s 17/17 clean record covers only Retatrutide, Tirzepatide, and GHK-Cu.
• Affiliate-promotion disclosure concern — medium: One Reddit account posted as an apparent vendor representative with WhatsApp/Telegram contact details and no visible disclosure; no broad public coupon network was found.